ホーム>>Signaling Pathways>> Cell Cycle/Checkpoint>> RAD51>>CAM833

CAM833

カタログ番号GC65935

CAM833 は、BRCA2 と RAD51 の間の相互作用の強力なオルソステリック阻害剤であり、ChimRAD51 タンパク質に対する Kd は 366 nM です。 CAM833 は RAD51 のオリゴマー化も阻害します。

Products are for research use only. Not for human use. We do not sell to patients.

CAM833 化学構造

Cas No.: 2758364-02-0

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$419.00
在庫あり
1mg
$164.00
在庫あり
5mg
$360.00
在庫あり
10mg
$612.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a Kd of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization[1].

CAM833 (3.125-50 μM; 24 h) causes a concentration-dependent decrease in RAD51 foci and subsequent increase in DNA damage[1].
CAM833 (25 μM) inhibits RAD51 molecular clustering at DNA damage sites[1].
CAM833 (0-50 μM) inhibits DNA repair by homologous recombination[1].
CAM833 (20 μM; 0-72 h) potentiates radiation-induced cell-cycle arrest and increases apoptosis over time[1].
CAM833 (10 μM) causes a dose-dependent growth inhibition that is enhanced when combined with ionizing radiation[1].
CAM833 (20 μM; 96 h) potentiates the growth suppressive effect of PARP1 inhibition in BRCA2 wild-type cells[1].

Cell Cycle Analysis[1]

Cell Line: HCT116 cells
Concentration: 20 μM
Incubation Time: 0-72 h
Result: In the control the percentage of cells in the apoptotic subG1 fraction remains below 5% throughout, in the compound-treated cells this rises progressively to peak at 15% at 48 hours.

レビュー

Review for CAM833

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CAM833

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.